Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy

SIMPLE SUMMARY: Despite the immense progress in systemic treatment of advanced unresectable melanoma with immunotherapies, there is still an unmet need for patients showing primary resistance. We show that addition of intratumoral injections of the immune modulator Interleukin-2 can overcome primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafei-Shamsabadi, David, Lehr, Saskia, Behrens, Max, Meiss, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833633/
https://www.ncbi.nlm.nih.gov/pubmed/35158808
http://dx.doi.org/10.3390/cancers14030540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833633/
https://www.ncbi.nlm.nih.gov/pubmed/35158808
http://dx.doi.org/10.3390/cancers14030540

Ejemplares similares